GhostLabz ARA-290 10mg vial
-22%
4X Tested - ISO 17025
98.70% View COA
Neuroprotective Peptide

ARA-290

Certificate of Analysis

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from helix B of erythropoietin, studied for selective activation of the innate repair receptor without stimulating red blood cell production.

BUNDLE & SAVE
2-Day Shipping

Free Shipping
over $200

Free shipment
protection

Secure Checkout
256-bit SSL

Description

What is ARA-290?

ARA-290, also known as cibinetide, is an 11-amino-acid peptide derived from the helix B domain of the erythropoietin (EPO) molecule. Unlike full-length EPO, ARA-290 binds selectively to the innate repair receptor (IRR), a heteromeric complex of the EPO receptor and the beta-common receptor (CD131), and does not stimulate erythropoiesis.

The innate repair receptor is upregulated on injured or metabolically stressed tissue, including neurons, immune cells, and vascular endothelium. By engaging this pathway rather than the classical homodimeric EPO receptor, ARA-290 has been studied in preclinical models for modulation of inflammatory signaling, nerve fiber integrity, and tissue protection following injury.

ARA-290 has advanced into Phase 2 clinical investigation for sarcoidosis-associated small fiber neuropathy and for neuropathic pain in type 2 diabetes, with endpoints including corneal nerve fiber density and patient-reported pain measures. Because it lacks erythropoietic activity, it does not carry the hematocrit-related effects associated with EPO itself.

ARA-290 is not approved by the FDA or any other regulatory agency. It is sold strictly for laboratory and research purposes only.

Research Applications

Areas of Investigation
Receptor Signaling

Innate Repair Receptor Activation

Studied for selective binding to the EPO receptor / CD131 heteromer expressed on stressed and injured tissue, without engaging the erythropoietic receptor.
Neuropathy

Small Fiber Neuropathy Research

Investigated in Phase 2 trials for sarcoidosis-associated small fiber neuropathy, with corneal nerve fiber density used as an objective endpoint.
Inflammation

Inflammatory Modulation

Preclinical models have examined dampened pro-inflammatory cytokine signaling and reduced tissue damage following ischemic and inflammatory insult.
Metabolism

Metabolic and Glycemic Research

Explored in type 2 diabetes models for effects on neuropathic pain scores and markers of glycemic control alongside nerve fiber measures.

Compound Profile

Technical specifications
What is ARA-290?

Molecular Profile

Sequence
Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (pGlu-EQLERALNSS)
Molecular Formula
C₅₁H₈₄N₁₆O₂₁
Molecular Weight
1,257.33 g/mol
Appearance
White lyophilized powder

Form

Lyophilized (freeze-dried)
Handling & Shelf Life Guidelines

Storage & Stability

Storage (Pre-Reconstitution)

Store below -20°C, desiccated, away from light and moisture.
Storage (Post-Reconstitution)
Refrigerate at 2–8°C. For longer storage, aliquot and store below -18°C. Avoid freeze-thaw cycles.
Shelf Life
24 months from date of manufacture when stored as directed
Sensitivity Notes
Sensitive to heat, light, and moisture. Keep sealed until use.
Compliance & Clinical Overview

Regulatory & Research Status

FDA Status
Not approved for human use. Investigational compound that has received FDA orphan drug designation for sarcoidosis-associated small fiber neuropathy.
WADA Classification
Not specifically named on the WADA Prohibited List. EPO receptor agonists fall under class S2; ARA-290 is non-erythropoietic, and status may be interpreted under S0 (Non-Approved Substances).
Clinical Trial Status
Peer-reviewed preclinical and Phase 2 clinical literature covering innate repair receptor pharmacology, corneal nerve fiber density, and neuropathic pain endpoints.
Published Studies
Peer-reviewed preclinical and Phase 2 clinical literature covering innate repair receptor pharmacology, corneal nerve fiber density, and neuropathic pain endpoints.
Research Disclaimer
Investigational research compound. For laboratory and research purposes only. Not intended for human consumption.

COA's (Certificate of Analysis)

Third Party Tested by Freedom Diagnostics
98.70%
Purity
Variant
ARA-290
Lot #
GL-2609-003
Labelled
10mg
Actual
10.29mg
Tested
9/21/2026
View COA
(opens in a new tab)
99.75%
Purity
Variant
ARA-290
Lot #
ARA10-GL01
Labelled
10mg
Actual
10.46mg
Tested
7/31/2026
View COA
(opens in a new tab)

Frequently Asked Questions

Common questions about ARA-290 research